Alifax Presents First Automated System for Bacterial Culture and Susceptibility Testing at ECCMID 2022
Posted on 22 Apr 2022
Alifax S.r.l. (Padua, Italy) presented the world’s first automated system for bacterial culture and susceptibility testing at the 32nd edition of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) held in Lisbon, Portugal on 23 - 26 April 2022. ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together more than 14,000 colleagues from all over the world.
At this year’s ECCMID, Alifax presented Alfred 60AST, the first fully automated system able to perform bacterial culture, RAA and susceptibility testing by automating the whole process of sample inoculation, reading and result transmission. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity. The CE - IVD Marked Alfred 60AST monitors the growth phases of bacteria from the inoculum step into specific culture broths providing real time growth curves and quantitative bacterial count results in CFU/ml.
Alifax also demonstrated HB&L, the first analyzer for bacterial culture and susceptibility testing in human biological fluids and urine. HB&L is the first analyser able to perform bacterial culture, RAA test and susceptibility testing on samples such as urine, sterile or non sterile fluids and other biological samples. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity.
Related Links:
Alifax S.r.l.
